http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021002373-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6fd79dd62e3c4ad23cfaac18304c47ab |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb31a02dcfa0fe2204236df80643d936 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26ca328eb1384ffa840364304eeab309 |
| publicationDate | 2021-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2021002373-A1 |
| titleOfInvention | KLRG1 Binding Compositions and Methods of Use Thereof |
| abstract | Compositions that bind to killer cell lectin-like receptor G1 (KLRG1) or its ligands are provided. The compositions can agonize or antagonize signal transduction through KLRG1. For example, some compositions either inhibit or block signal transduction through KLRG1 while other compositions induce or enhance signal transduction through KLRG1. In some embodiments, the compositions are anti-KLRG1 antibodies, KLRG1 fusion proteins, or KLRG1 ligand fusion proteins. One embodiment provides antibodies and antigen binding fragments thereof that immuno specifically bind KLRG1 and block, inhibit or reduce signal transduction through KLRG1. In another embodiment, the antibodies specifically bind to human KLRG1 under physiological conditions. In certain embodiments, the antibodies bind to KLRG1 that is arrayed on the surface of a cell; arrayed on the surface of a cell at an endogenous concentration; arrayed on the surface of a live cell, and inhibits or blocks interaction of KLRG1 and a ligand of KLRG1; or a combination thereof. In a preferred embodiment, the antibody or antigen binding fragment thereof binds to the extracellular domain of KLRG1 expressed on an immune cell including, but not limited to natural killer cells and T cells. Methods of using the compositions are also provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11180561-B2 |
| priorityDate | 2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1415.